Amylyx Pharmaceuticals (NASDAQ:AMLX) said its pivotal Phase III LUCIDITY trial of avexitide in post-bariatric hypoglycemia, or PBH, has completed final patient visits, with top-line data expected in late August or early September. She said Amylyx has been “very diligent” because the database will be locked once for the 16-week double-blind core study. Monahan said Amylyx has identified care settings with 50 to 60 PBH patients and, in some instances, up to 100 patients. The company said it is continuing to assess the most efficient design for a potential Phase III trial in the multifactorial rare disease. About Amylyx Pharmaceuticals (NASDAQ:AMLX)Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases.